Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

Published: 12/01/2019
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Source: WWW.BUSINESSWIRE.COM

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Knight Therapeutics have entered into an exclusive license agreement to commercialize NERLYNX® (neratinib) in Canada.

Read more
Related news
Comment